O’Melveny & Myers and Jingtian & Gongcheng have advised Chinese medical device company Peijia Medical on its HK$2.34 billion ($302 million) IPO on the Hong Kong Stock Exchange, with Herbert Smith Freehills and Commerce & Finance Law Offices representing the underwriters.

This was the third healthcare company to list in Hong Kong since the coronavirus outbreak in late January. Also advising Peijia were Campbells Law Firm, Hengtai Law Offices, and Guangdong Junlong Law Firm

Peijia Medical is a medical devices provider of heart and neurovascular diseases equipment specifically offering services for Chinese patients and healthcare providers.

The Herbert Smith team was led by partners Matt Emsley, Siddhartha Sivaramakrishnan and Stanley Xie.

 

To contact the editorial team, please email ALBEditor@thomsonreuters.com.

Related Articles

开年“扎堆”,内地茶饮企业或将引领今年的香港IPO市场(ZH/EN)

中国的新茶饮连锁店正在加速攻占中国一线城市和下沉市场的街头巷尾、百货商场。在资本市场,它们之间的争速则在另一个“战场”展开:港交所。

竞天公诚、方达领衔药明合联香港IPO,创当年度纪录(ZH/EN)

by Mari Iwata |

近日,药明合联于香港交所主板成功上市,成为今年迄今为止在香港的第三大IPO,以及最大医疗健康和生物科技IPO项目。

汉坤、通商、达辉等助力极兔登陆港交所(ZH/EN)

中国快递公司极兔速递成功以同股不同权架构在香港完成上市,募资额为35.3亿港元。世达国际律师事务所、汉坤律师事务所、通商律师事务所担任联席保荐人的法律顾问,瑞生国际律师事务所、达辉律师事务所、衡力斯律师事务所则为发行人提供法律服务。